Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) 3-Year Book Growth Rate : -29.80% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Reviva Pharmaceuticals Holdings 3-Year Book Growth Rate?

Reviva Pharmaceuticals Holdings's Book Value per Share for the quarter that ended in Mar. 2024 was $0.00.

During the past 12 months, Reviva Pharmaceuticals Holdings's average Book Value per Share Growth Rate was -117.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was -29.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 5 years, the highest 3-Year average Book Value per Share Growth Rate of Reviva Pharmaceuticals Holdings was -29.80% per year. The lowest was -29.80% per year. And the median was -29.80% per year.

Competitive Comparison of Reviva Pharmaceuticals Holdings's 3-Year Book Growth Rate

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's 3-Year Book Growth Rate falls into.

Reviva Pharmaceuticals Holdings 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Reviva Pharmaceuticals Holdings (NAS:RVPHW) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Reviva Pharmaceuticals Holdings 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPHW) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

RVPH:USA

Address

19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014

Website

https://www.revivapharma.com

Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.